Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rescue Therapy for Helicobacter pylori.

Wai K. Leung1, David Y. Graham

  • 1Digestive Diseases Section, Veterans Affairs Medical Center (111D), 2002 Holcombe Boulevard, Houston, TX 77030, USA dgraham@bcm.tmc.edu

Current Treatment Options in Gastroenterology
|March 7, 2002
PubMed
Summary

Standard Helicobacter pylori treatment fails in up to 35% of patients. Antimicrobial resistance necessitates tailored therapies, with bismuth quadruple therapy recommended as the best salvage treatment when susceptibility testing is unavailable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Up to 35% of patients experience treatment failure with standard anti-Helicobacter pylori (H. pylori) therapies.
  • Increasing antimicrobial resistance is expected to further elevate failure rates of conventional proton pump inhibitor-based triple therapy.
  • Limited data exists for second-line or rescue therapies, often confounded by biases.

Purpose of the Study:

  • To review current strategies for managing H. pylori infections, particularly in the context of rising antimicrobial resistance.
  • To evaluate the efficacy of various treatment regimens, including standard, second-line, and salvage therapies.
  • To emphasize the importance of antibiotic resistance testing for optimizing H. pylori eradication.

Main Methods:

Related Experiment Videos

  • Literature review of studies on H. pylori treatment failure and antimicrobial resistance.
  • Analysis of data regarding the effectiveness of different therapeutic approaches, including triple therapy, quadruple therapy, and salvage regimens.
  • Evaluation of recommendations for pretreatment antibiotic resistance testing and empirical treatment strategies.

    • Main Results:

    • Pretreatment antibiotic resistance testing is crucial for tailoring H. pylori treatment regimens.
    • Switching between clarithromycin and metronidazole may be considered for empirical second-line therapy if resistance is unknown.
    • Bismuth-containing quadruple therapy is the most effective salvage treatment in the absence of susceptibility data.
    • Furazolidone quadruple and rifabutin triple therapies are salvage options of last resort, requiring culture and susceptibility testing if they fail.

    Conclusions:

    • Optimizing H. pylori eradication requires a shift towards personalized treatment based on antimicrobial susceptibility.
    • Bismuth-containing quadruple therapy offers a reliable salvage option for refractory H. pylori infections.
    • Further research into effective second-line and salvage therapies is needed, especially in high-resistance settings.